

## Sudan virus-like particles (SUDV VLP)

**Catalog #:** 0567-001

**Lot #:** 1706003

**Description:** Virus-like Particles (VLP's) expressing recombinant Sudan virus (SUDV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). These VLP's are produced in Sf9 insect cells through infection with a recombinant baculovirus.


**Storage:** 2-3 weeks at -20°C, -80°C long term

**Size:** 1 mg of protein supplied in PBS (supplemented with glycerol, arginine and glutamic acid) at a concentration of **2.073 mg/mL**.

**Relevance:** Since these VLP's mimic Sudan virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and also as a tool to enhance filovirus research.

**Related Products:** IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, [www.ibtbioservices.com](http://www.ibtbioservices.com) for more details.

### Western Blot Detection



Western Blot was used to confirm the presence of Sudan-specific GP, NP and VP40 in the VLP. VLP sample was heat-denatured under reducing condition and loaded at 500 ng/lane (A) and 100 ng/lane (B & C).

(A) GP was detected as a broadly-diffused band ~37-160 kDa using 0.1 µg/mL of Anti-SUDV GP mAb (2H5) (cat # 0202-029)

(B) NP was detected as multiple bands at ~70-110 kDa using 0.1 µg/mL of Anti-SUDV NP pAb (cat# 0302-012)

(C) VP40 was detected as multiple protein bands with one duplet band at ~40 kDa and a strong band at ~20 kDa using 0.1 µg/mL of Anti-SUDV VP40 pAb (cat# 0302-001)

**Intended for research use only, not for human, therapeutic, or diagnostic applications.**

*The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.*

**Copyright 2017. Integrated BioTherapeutics, Inc. All rights reserved.**